Becton, Dickinson and Company (BDX): Price and Financial Metrics


Becton, Dickinson and Company (BDX)

Today's Latest Price: $221.34 USD

0.18 (0.08%)

Updated Sep 25 11:54am

Add BDX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 138 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BDX Stock Summary

  • With a market capitalization of $64,107,328,739, Becton Dickinson & Co has a greater market value than 97.07% of US stocks.
  • Becton Dickinson & Co's stock had its IPO on January 1, 1986, making it an older stock than 92.81% of US equities in our set.
  • The volatility of Becton Dickinson & Co's share price is greater than that of merely 2.35% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to BDX, based on their financial statements, market capitalization, and price volatility, are BSX, ZTS, SYK, ABB, and SE.
  • Visit BDX's SEC page to see the company's official filings. To visit the company's web site, go to www.bd.com.
BDX Daily Price Range
BDX 52-Week Price Range

BDX Stock Price Chart Technical Analysis Charts


BDX Price/Volume Stats

Current price $221.34 52-week high $286.72
Prev. close $221.16 52-week low $197.75
Day low $219.50 Volume 703,257
Day high $222.55 Avg. volume 1,992,432
50-day MA $252.47 Dividend yield 1.43%
200-day MA $252.31 Market Cap 64.16B

Becton, Dickinson and Company (BDX) Company Bio


Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$221.34$160.68 -27%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Becton Dickinson & Co. To summarize, we found that Becton Dickinson & Co ranked in the 36th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 27%. The most interesting components of our discounted cash flow analysis for Becton Dickinson & Co ended up being:

  • The company has produced more trailing twelve month cash flow than 87.45% of its sector Healthcare.
  • Becton Dickinson & Co's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 22.45% of tickers in our DCF set.
  • Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-29%
1%-28%
2%-27%
3%-27%
4%-26%
5%-25%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BDX, try IQV, ITGR, EDAP, CRL, and NVS.


BDX Latest News Stream


Event/Time News Detail
Loading, please wait...

BDX Latest Social Stream


Loading social stream, please wait...

View Full BDX Social Stream

Latest BDX News From Around the Web

Below are the latest news stories about Becton Dickinson & Co that investors may wish to consider to help them evaluate BDX as an investment opportunity.

Becton Dickinson probes false-positive COVID-19 test results in U.S. nursing homes

Becton Dickinson said on Tuesday it is investigating reports from U.S. nursing homes that its rapid coronavirus testing equipment is producing false-positive results. Tests conducted on the company's Veritor Plus system for detecting the virus are reporting multiple false positive results in some cases, Becton said. The inaccurate results were first reported https://www.wsj.com/articles/covid-19-test-maker-examines-false-positive-results-in-nursing-homes-11600121878?mod=searchresults&page=1&pos=6 by the Wall Street Journal.

Yahoo | September 15, 2020

PRESS DIGEST- Wall Street Journal - Sept 15

Yahoo | September 15, 2020

Becton Dickinson (BDX) Down 9.8% Since Last Earnings Report: Can It Rebound?

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 5, 2020

The Top 5 Buys of the MS Global Franchise Fund

Fund releases 2nd-quarter portfolio

Yahoo | September 4, 2020

It Might Not Be A Great Idea To Buy Becton, Dickinson and Company (NYSE:BDX) For Its Next Dividend

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Becton...

Yahoo | September 3, 2020

Read More 'BDX' Stories Here

BDX Price Returns

1-mo -12.56%
3-mo -4.92%
6-mo 2.88%
1-year -10.50%
3-year 18.38%
5-year 74.49%
YTD -17.80%
2019 22.20%
2018 6.61%
2017 31.24%
2016 9.22%
2015 12.63%

BDX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BDX Dividend History

Continue Researching BDX

Here are a few links from around the web to help you further your research on Becton Dickinson & Co's stock as an investment opportunity:

Becton Dickinson & Co (BDX) Stock Price | Nasdaq
Becton Dickinson & Co (BDX) Stock Quote, History and News - Yahoo Finance
Becton Dickinson & Co (BDX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8041 seconds.